在低心力输出综合征的最佳内托普支持策略
Travis J Miles1, Kyle W Blackburn1, Marc R Moon2
1Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Seminars in thoracic and cardiovascular surgery
|April 20, 2025
概括
心脏手术后的低心力输出综合征 (LCOS) 需要量身定制的治疗. 本综述指导了用于更好的血液动力学管理和患者结果的异型药物和血管压缩剂的个性化使用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 低心输出综合征 (LCOS) 是心脏手术后的一种严重并发症.
- 它显著增加了患者的发病率和死亡率.
- 目前的管理依赖于内和血管压缩剂,但最佳策略缺乏可靠的比较数据.
研究的目的:
- 审查目前关于LCOS管理药理学策略的证据.
- 倡导基于患者血液动力学的个性化治疗方法.
- 为在特定临床场景中使用可用的血管活性剂提供指导.
主要方法:
- 对现有关于LCOS药理管理的文献进行系统审查.
- 关于内和血管压缩剂的证据综合.
- 对个性化血管活性剂选择的临床背景的分析.
主要成果:
- 有限的随机数据存在,用于比较LCOS中的单个异构物.
- 对于LCOS治疗的实践模式是高度可变的.
- 建议采用个性化的方法,考虑血液动力学概况.
结论:
- 对LCOS的个性化药理管理至关重要.
- 提供了根据患者需求选择血管活性剂的指导.
- 需要进行进一步的研究来比较LCOS的内类药物.
相关概念视频
Heart Failure Drugs: Inotropic Agents
416
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
416
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K
Pathophysiology of Cardiac Performance
488
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
488


